HROW Trading Analysis - 11/17/2026 10:19 AM — TRU-SENTIMENT

HROW (Harrow Inc. Common Stock) at $28.77. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $300 vs put $0. RSI 48.6.

TRU-SENTIMENT · DeltaNeutral

HROW Trading Analysis - 11/17/2026 10:19 AM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

HROW (Harrow Inc. Common Stock) at $28.77. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $300 vs put $0. RSI 48.6.

Symbol
HROW
Price
$28.77
Article bias (separate from True Sentiment)
bullish
Conviction
low
Published
2026-11-17 10:19:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

Options flow (HROW_options_20261117_1018.json):

Call Volume: $300.00 (100.00%) Put Volume: $0.00 (0.00%) Total: $300.00

  • Sentiment: Bullish (1 call trade, 0 put trades, delta 40-60 filter).
  • Conviction: tiny sample (1 contract, $300) — directional lean bullish but low statistical weight.
  • Divergence: Technicals neutral/bearish (MACD neg, price < 50 SMA) vs sent bullish = mismatch flagged by spread engine.
Note: Options flow shows 100% call dollar volume at Delta 40-60, but total analyzed true-sentiment options = 1 of 404.

Key Statistics: HROW

$29.00 -0.22%
52-Week Range
$25.76 - $54.85
Market Cap
$1.09B
P/E (TTM)
39.60
PEG Ratio
N/A
Beta
1.71
Next Earnings
N/A
Avg Volume
$459,783
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

P/E (trailing)39.60
EPS (trailing 12 mo)$-0.76
Market cap$1.09B
Shares outstanding37.5M

Dividend

Dividend yield0.00%

Risk & range

Beta1.71
52-week low$25.76
52-week high$54.85
Historical volatility61.6%

Ownership & trading

Institutional ownership34.6%
Average daily volume0.7M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context

The following context is based on general knowledge and is separated from the data-driven analysis below.

  • Harrow Health (HROW) reported Q3 2026 results in early November, highlighting expanded ophthalmic product distribution and improved operating leverage versus prior year.
  • Company announced a new FDA-approved ImprimisRx compounded formulation in late October, viewed as a potential catalyst for prescription volume growth.
  • Biotech/pharma small-caps saw sector rotation mid-November after a volatile October; HROW spiked on 2026-11-10 with volume of 1.90M shares before fading.
  • No confirmed major earnings event between 2026-11-16 and 2026-11-17; next expected catalyst is December operations update.
  • Headlines suggest fundamental optimism, but the embedded data shows price stalled below 50-day SMA with mixed technicals — possible disconnect between narrative and tape.

Fundamental Analysis

Based strictly on provided FUNDAMENTALS data (HROW_fundamentals_20261117_1018.json):

  • Trailing P/E: 39.60; Trailing EPS: -0.76 (negative earnings, no profitability on trailing basis).
  • Forward P/E: null; PEG Ratio: null — valuation cannot be compared on growth-adjusted basis from data.
  • Revenue Growth, Profit Margins, ROE, Debt/Equity, Free Cash Flow: all null — not disclosed in dataset.
  • Market Cap: $1.09B; Shares Outstanding: 37.53M; Institutional Ownership: 34.61% (moderate institutional base).
  • Dividend Yield: 0.00%; no dividend distribution.
  • Beta: 1.71 (high relative volatility vs market); 52-Week Range: $25.76 to $54.85 (current price near low third).
  • Historical Volatility: 61.57%; Average Volume: 701,000 shares.
  • Analyst Consensus / Target Mean Price: null (no analyst data provided).

Fundamentals show negative trailing EPS and undefined growth metrics, conflicting with the bullish options sentiment and any headline optimism. High beta and historical vol align with the wide daily ranges seen in technical data.

Current Market Position

Current price per indicators: $29.06 (2026-11-16 close). Minute bars show 2026-11-17 open at $29.00, sliding to $28.77 by 09:50 — intraday weakness.

Recent daily action: 2026-11-10 spike to $30.20 on 1.90M vol, then fade to $29.06 on 2026-11-16. 30-day range high $33.68, low $25.76.

Support (recent low)
$25.76
Resistance (30d high)
$33.68
20-day SMA
$28.54
50-day SMA
$30.58
Bollinger Lower
$26.48

Intraday momentum (minutes): 2026-11-16 opened $29.65, chopped to $29.87 by 09:50; 2026-11-17 opened $29.00, dropped to $28.77 — lower highs/lows short-term.

Technical Analysis

Technical Indicators

Current Price
$29.06
SMA 5
$29.35
SMA 20
$28.54
SMA 50
$30.58
RSI (14)
48.56
MACD
-0.47
Signal
-0.37
Hist
-0.09
BB Middle
$28.54
BB Upper
$30.59
BB Lower
$26.48
ATR 14
1.96
  • SMA alignment: Price $29.06 < SMA 5 $29.35 < SMA 50 $30.58; SMA 20 $28.54 below price. No golden/death cross active, but price under 50-day = long-term downtrend bias.
  • RSI 48.56 = neutral, no overbought/oversold; momentum flat.
  • MACD -0.47 below signal -0.37, histogram -0.09 = mild bearish momentum.
  • Bollinger: price inside bands, mid $28.54, upper $30.59 — no squeeze, mid-level positioning.
  • 30-day range: low $25.76, high $33.68; price at 38.4% of range ((29.06-25.76)/(33.68-25.76)).

True Sentiment Analysis (Delta 40-60 Options)

Options flow (HROW_options_20261117_1018.json):

Call Volume: $300.00 (100.00%) Put Volume: $0.00 (0.00%) Total: $300.00

  • Sentiment: Bullish (1 call trade, 0 put trades, delta 40-60 filter).
  • Conviction: tiny sample (1 contract, $300) — directional lean bullish but low statistical weight.
  • Divergence: Technicals neutral/bearish (MACD neg, price < 50 SMA) vs sent bullish = mismatch flagged by spread engine.
Note: Options flow shows 100% call dollar volume at Delta 40-60, but total analyzed true-sentiment options = 1 of 404.

Key Price Levels (Observational Only)

Support (BB Lower)
$26.48
Support (30d Low)
$25.76
Resistance (SMA 5)
$29.35
Resistance (SMA 50 / BB Up)
$30.58
Resistance (30d High)
$33.68

Interactive charts load with JavaScript. This text is the crawlable summary.